Sector News

Galapagos CSO Wigerinck hits the bricks after major setbacks

June 27, 2021
Life sciences

Piet Wigerinck, Ph.D., is set to step down as chief scientific officer of Galapagos later this year. The departure follows a series of setbacks that have left Galapagos struggling to rebuild confidence in its diminished pipeline.

Wigerinck joined Galapagos in 2008 and stepped up to the CSO post four years later. Over his time at Galapagos, Wigerinck oversaw the Belgian biotech’s first clinical trial and the phase 2 FITZROY and DARWIN studies of the once-hyped JAK1 inhibitor filgotinib. Now, with Galapagos reeling from the FDA’s rejection of filgotinib and the failure of a phase 3 ziritaxestat trial, Wigerinck is moving on.

Walid Abi-Saab, M.D., chief medical officer at Galapagos, has taken over the early-stage development tasks previously handled by Wigerinck. However, although, the transfer of power is immediate, Wigerinck will stick around for the next five months to steer research while Galapagos looks for a new leader.

Wigerinck is leaving at a point when his legacy is uncertain. While filgotinib has come to market in the EU, Gilead Sciences has dropped plans to seek FDA approval in rheumatoid arthritis, and it is doubtful whether the drug will ever live up to pre-rejection blockbuster sales forecasts. Ziritaxestat, another drug that advanced under Wigerinck, failed a phase 3 idiopathic pulmonary fibrosis trial.

The setbacks raised concerns about R&D decision-making at Galapagos, which responded to the blows by assessing the process it uses to advance compounds, pulling out of certain early research areas and stopping development of some assets as part of a push to save 150 million euros ($179 million).

However, it remains possible that some of the assets that advanced into early-stage development under the leadership of Wigerinck will go on to be clinical and commercial successes. Galapagos CEO Onno van de Stolpe picked out TYK2 inhibitor GLPG3667 and SIK2/SIK3 inhibitor GLPG3970 as part of the “considerable legacy” of the departing CSO.

Setbacks to other assets have ramped up the importance of upcoming readouts on the two drugs, both for Wigerinck’s legacy and Galapagos’ prospects of recovering from its recent travails. Data on GLPG3970 are due later this year. The impact of the readout extends beyond GLPG3970 to the wider SIK-focused “Toledo” program, which Galapagos has hyped up and bet big on.

by Nick Paul Taylor

Source: fiercebiotech.com

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend